Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The FDAs announcement that tirzepatide is no longer in shortage means compounding is now tightly restricted, and pharmacies may only prepare the medication for patients with verifiable clinical need that cannot be met by the FDA-approved formulation
I think that could be an alternate explanation to the extremely low levels of concomitant use of incretin-mimetic drugs with psychedelics.
If Phase 3 trials meet efficacy and safety endpoints, Eli Lilly may submit a BLA to the FDA
Bret: Yeah, and, do you think the burden of proof, though, is different from a medication that needs FDA-approval and is expensive and whatnot, and you need a physician to give it to you versus just changing how you eat
Ive done better losing weight here than I ever have before
